This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
+6
Published on July 15
With over a billion people worldwide suffering from hypertension and many struggling with current treatments, successful new therapies could achieve blockbuster status quickly.
AstraZeneca's success with baxdrostat has validated a completely new approach to treating resistant hypertension, potentially triggering renewed investment across the entire field.
We're witnessing a potential turning point in cardiovascular medicine that could boost valuations for companies involved in this space, especially as clinical successes accumulate.
AstraZeneca's successful baxdrostat trial has validated a new pathway for treating resistant hypertension. This breakthrough could reinvigorate the entire cardiovascular therapeutic landscape, potentially boosting valuations for companies developing novel treatments for hypertension and related conditions like kidney disease.
Hypertension affects over a billion people globally, with many struggling to control their blood pressure with existing medications. This represents a massive market opportunity for pharmaceutical companies that can develop effective new treatments with novel mechanisms of action.
These companies were selected for their leadership in cardiovascular, metabolic, and kidney disease research. From the headline-maker AstraZeneca to companies with complementary expertise in related conditions, each has potential to benefit from renewed interest in hypertension innovation.
Market capitalisation breakdown for the 'Hypertension Therapy Innovators' basket.
AZN: $258.54B
LLY: $756.76B
NVO: $180.85B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
ASTRAZENECA PLC
AZN
Current Price
$165.32
The company's successful Phase 3 trial for its novel hypertension drug, baxdrostat, is the primary catalyst for this theme. Its leadership in this spe...
The company's successful Phase 3 trial for its novel hypertension drug, baxdrostat, is the primary catalyst for this theme. Its leadership in this specific area makes it a core holding.
Eli Lilly & Co
LLY
Current Price
$1,279.99
A major pharmaceutical company with a strong and growing pipeline in cardiovascular and metabolic diseases, including treatments that indirectly benef...
A major pharmaceutical company with a strong and growing pipeline in cardiovascular and metabolic diseases, including treatments that indirectly benefit hypertensive patients.
NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS'B'DKK1
NVO
Current Price
$46.67
A global leader in diabetes and obesity care, conditions that are heavily co-morbid with hypertension. Its research into metabolic diseases has signif...
A global leader in diabetes and obesity care, conditions that are heavily co-morbid with hypertension. Its research into metabolic diseases has significant overlap.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+53.19%
On average, analysts expect assets in this group to grow 53.19% over the next year.
12 of 16 assets in this group are rated Buy by professional analysts.
